Flow rate variance of a fully implantable pump for the delivery of intravenous treprostinil in pulmonary arterial hypertension

Flow rate variance of a fully implantable pump for the delivery of intravenous treprostinil in pulmonary arterial hypertension

Implantable infusion pumps might improve the convenience and safety of intravenous treprostinil for pulmonary arterial hypertension. The LENUS Pro® pump (approved in Europe) has a fixed flow rate. Based on 126 pumps and 2853 refills, we retrospectively analyzed the actual flow rate from 09/2010 to 0...

Full description

Bibliographic Details
Main Authors:	Manuel J. Richter, Satenik Harutyunova, Tom Bollmann, Simon Classen, Jan Fuge, Henning Gall, Felix Gerhardt, Hossein A. Ghofrani, Hartmut Gunkel, Ekkehard Grünig, Michael Halank, Alexander Heine, Hans Klose, Tobias J. Lange, Claus Neurohr, Kai Nickolaus, Christian F. Opitz, Stephan Rosenkranz, Hans-Jürgen Seyfarth, Khodr Tello, Ralf Ewert, Karen M. Olsson
Format:	Article
Language:	English
Published:	Wiley 2020-03-01
Series:	Pulmonary Circulation
Online Access:	https://doi.org/10.1177/2045894020910136

Similar Items

Phenotypes and treatment outcomes in idiopathic pulmonary arterial hypertension patients with comorbidities
by: Dirk Skowasch, et al.
Published: (2024-01-01)

Gene panel diagnostics reveals new pathogenic variants in pulmonary arterial hypertension
by: Christina A. Eichstaedt, et al.
Published: (2022-03-01)

Intravenous treprostinil via an implantable pump in pediatric pulmonary arterial hypertension
by: Susanna Desole, et al.
Published: (2018-12-01)

Practical management of riociguat in patients with pulmonary arterial hypertension
by: Michael Halank, et al.
Published: (2019-08-01)

Impact of SARS-CoV-2 pandemic on pulmonary hypertension out-patient clinics in Germany: a multi-centre study
by: Athiththan Yogeswaran, et al.
Published: (2020-07-01)

Characterisation of cough evoked by inhaled treprostinil and treprostinil palmitil
by: Richard W. Chapman, et al.
Published: (2021-02-01)

Exercise training improves exercise capacity and quality of life in patients with inoperable or residual chronic thromboembolic pulmonary hypertension.
by: Christian Nagel, et al.
Published: (2012-01-01)

Is iron deficiency caused by BMPR2 mutations or dysfunction in pulmonary arterial hypertension patients?
by: Vivienne Theobald, et al.
Published: (2023-04-01)

Mutually reinforcing effects of genetic variants and interferon-β 1a therapy for pulmonary arterial hypertension development in multiple sclerosis patients
by: Marianne Lerche, et al.
Published: (2019-09-01)

Treprostinil for pulmonary hypertension
by: Nika Skoro-Sajer, et al.
Published: (2008-06-01)

Profiles and treatment patterns of patients with pulmonary arterial hypertension on monotherapy at experienced centres
by: Max Wissmüller, et al.
Published: (2022-10-01)

Myeloproliferative Diseases as Possible Risk Factor for Development of Chronic Thromboembolic Pulmonary Hypertension—A Genetic Study
by: Christina A. Eichstaedt, et al.
Published: (2020-05-01)

Implementing the EXPEDITE parenteral induction protocol: Rapid parenteral treprostinil titration and transition to oral treprostinil
by: John F. Kingrey, et al.
Published: (2023-07-01)

Monotherapy in patients with pulmonary arterial hypertension at four German PH centres
by: Beate Stubbe, et al.
Published: (2021-04-01)

Tolerability, safety and survival in patients with severe pulmonary arterial hypertension treated with intravenous epoprostenol (Veletri®): a prospective, 6-months, open label, observational, non-interventional study
by: Julia Degering, et al.
Published: (2023-01-01)

Inhaled treprostinil: a therapeutic review
by: Channick RN, et al.
Published: (2012-01-01)

The risk profile change in patients with severe chronic thromboembolic pulmonary hypertension treated with subcutaneous treprostinil
by: Pavel Jansa, et al.
Published: (2023-07-01)

Risk stratification and prognostic factors in patients with pulmonary arterial hypertension and comorbidities a cross-sectional cohort study with survival follow-up
by: Panagiota Xanthouli, et al.
Published: (2020-05-01)

Periprocedural safety and outcome after pump implantation for intravenous treprostinil administration in patients with pulmonary arterial hypertension
by: Jan C. Kamp, et al.
Published: (2021-05-01)

Experiences with treprostinil in the treatment of pulmonary arterial hypertension
by: Amanda R. Stream, et al.
Published: (2012-10-01)

Successful management of an inadvertent excessive treprostinil overdose
by: Hohenforst-Schmidt W, et al.
Published: (2013-03-01)

Prognostic Relevance of Cardiopulmonary Exercise Testing for Patients with Chronic Thromboembolic Pulmonary Hypertension
by: Ralf Ewert, et al.
Published: (2022-10-01)

Validity of echocardiographic tricuspid regurgitation gradient to screen for new definition of pulmonary hypertension
by: Henning Gall, et al.
Published: (2021-04-01)

Resolution of Severe Portopulmonary Hypertension With Inhaled Treprostinil and Liver Transplantation
by: Alex J. Chang, MD, et al.
Published: (2024-03-01)

Design, Development, and Evaluation of Treprostinil Embedded Adhesive Transdermal Patch
by: Ibrahim Alissa, et al.
Published: (2023-04-01)

Effect of Inhalation Profile on Delivery of Treprostinil Palmitil Inhalation Powder
by: Helena Gauani, et al.
Published: (2023-03-01)

Evaluation and Selection of the Inhaler Device for Treprostinil Palmitil Inhalation Powder
by: Helena Gauani, et al.
Published: (2022-04-01)

Oral treprostinil use in children: a multicenter, observational experience
by: Usama Kanaan, et al.
Published: (2019-07-01)

Transitioning selexipag to oral treprostinil in patients with pulmonary artery hypertension
by: Carlo Arevalo, et al.
Published: (2022-01-01)

Dosing characteristics of oral treprostinil in real-world clinical practice
by: Vijay P. Balasubramanian, et al.
Published: (2018-07-01)

Prognostic meaning of right ventricular function and output reserve in patients with systemic sclerosis
by: Panagiota Xanthouli, et al.
Published: (2022-07-01)

Advanced risk stratification of intermediate risk group in pulmonary arterial hypertension
by: Athiththan Yogeswaran, et al.
Published: (2020-10-01)

Acute response to rapid iloprost inhalation using the Breelib™ nebulizer in pulmonary arterial hypertension: the Breelib™ acute study
by: Manuel J. Richter, et al.
Published: (2019-09-01)

Right heart size and function significantly correlate in patients with pulmonary arterial hypertension – a cross-sectional study
by: Lukas Fischer, et al.
Published: (2018-11-01)

Treprostinil Reconstitutes Mitochondrial Organisation and Structure in Idiopathic Pulmonary Fibrosis Cells
by: Lei Fang, et al.
Published: (2023-07-01)

Failure to tolerate continuous subcutaneous treprostinil in pediatric pulmonary hypertension patients
by: Julia McSweeney, et al.
Published: (2023-04-01)

Real‐world dosing characteristics and utilization of parenteral treprostinil in the outpatient setting
by: Vijay P. Balasubramanian, et al.
Published: (2022-01-01)

Implantable system for treprostinil: a real-world patient experience study
by: Shelley Shapiro, et al.
Published: (2020-04-01)

Oral treprostinil in transition or as add-on therapy in pediatric pulmonary arterial hypertension
by: D. Dunbar Ivy, et al.
Published: (2019-07-01)

Reduction of <i>BMPR2</i> mRNA Expression in Peripheral Blood of Pulmonary Arterial Hypertension Patients: A Marker for Disease Severity?
by: Vivienne Theobald, et al.
Published: (2022-04-01)